The use of monoclonal antibodies to treat Castleman's disease.
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder presenting with heterogeneous clinical features and with a complex etiology. MCD incidence is increased in people living with HIV/AIDS when it is causally associated with Kaposi's sarcoma-associated herpes virus (KSHV). HIV-seronegative individuals present with either idiopathic or KSHV-associated MCD. Central to MCD pathology is altered expression and signaling of IL-6, which promotes B-cell proliferation and causes systemic manifestations. KSHV encodes a viral homolog of human IL-6, accounting for its role in MCD, while recent evidence shows an association between IL-6 receptor polymorphisms and idiopathic MCD. The increased understanding of mechanisms underlying the pathogenesis of MCD has guided the use of new monoclonal antibody therapies for treating this complex disorder.
National Centre for HIV Malignancy, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.
Rebecca C
RC
Robey
Salvinia
S
Mletzko
Charlotte
C
Colley
Kirsty
K
Balachandran
Mark
M
Bower
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology* / Q000821:virology; D005871:Castleman Disease / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy*; D049109:Cell Proliferation; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000453:epidemiology*; D006566:Herpesviridae Infections / Q000150:complications / Q000453:epidemiology*; D019288:Herpesvirus 8, Human / Q000502:physiology*; D006801:Humans; D007167:Immunotherapy; D015850:Interleukin-6 / Q000378:metabolism; D011110:Polymorphism, Genetic; D019947:Receptors, Interleukin-6 / Q000235:genetics
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D019947:Receptors, Interleukin-6